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                                 INTRODUCTION
Typhoid history 
Typhoid fever or enteric fever is an age-old disease known for centuries. Patients  may 
become delirious, the typhoid state for which the disease is named (typhus from the Greek, 
stupor). Its symptoms and epidemiology overlap with that of typhus (camp fever), so typhoid 
has been confused with this rickettsial disease for much of its history. The name typhoid 
implies a “typhus-like” condition, and these two disease have been clearly delineated only 
since the  mid-nineteenth century.  In England,  Huxham (1739) in his  “Essay on Fevers” 
described the Plymouth epidemic of 1737 and he distinguished between putrid typhus (febris 
putrida) and described nervous fever (febris nervosa lenta) or what is now recognized as 
typhoid.  By the nineteenth century, typhoid and typhus were recognized as disease with 
distinct  clinical  features.  The  great  Parisan  clinician  Pierre  –  Charles  –Alexandre  Louis 
named the condition fever typhoid in his major work on the disease in 1829. Carl Joseph 
Eberth described the typhoid organism in the issue of patients in 1880 and George Galfky 
isolated and grew this organism in 1884. Friz Kauffmann (1937) and Philip B. White (1926) 
studied the antigenic structures of the typhoid and typhoid –like bacteria in detail and the 
Kauffmann – White system classification became standard. This system classification of the 
genus Salmonella employs the H, O, and Vi antigenic specificities to identify a particular 
isolate.
Magnitude of the problem
Typhoid fever is a global health problem. Its real impact is difficult to estimate because the clinical picture is 
confused with those of many other febrile infections. On the basis of the literature 1, 2 and the incidence of typhoid 
fever recorded in control groups in large vaccine field trials with good laboratory support it has been estimated that 
approximately 17 million cases of typhoid fever and 600 000 associated deaths occur annually 3. The ratio of disease 
caused by S. typhi to that caused by S. paratyphi is about 10 to 1 in most of the countries where this matter has been 
studied. In areas of endemicity and in large outbreaks, most cases occur in persons aged between 3 and 19 years. 
Nevertheless, clinically apparent bacteraemic  S. typhi infection in children aged under three years has been described 
in Bangladesh, India, Jordan, Nigeria, and elsewhere. Between 1% and 5% of patients with acute typhoid infection 
have been reported to become chronic carriers of the infection in the gall bladder, depending on age, sex and 
treatment regimen. The propensity to become a carrier follows the epidemiology of gall bladder disease, increasing 
with age and being greater in females than in males.
The organism
Typhoid fever is caused by Salmonella typhi, a Gram-negative bacterium. A very similar but 
often less severe disease is caused by  Salmonella  serotype  paratyphi  A.  S. typhi can be 
identified in the laboratory by several biochemical and serological tests. One of the most specific 
serologic tests is that of polysaccharide capsule Vi, which is  present in about 90% of all freshly 
isolated S. typhi and has a protective effect against the bactericidal action of the serum of infected 
patients. This capsule provides the basis for one of the commercially available vaccines. Vi antigen is 
present in  some other  bacteria  (Citrobacter  freundii,  Salmonella  paratyphi  C  and  Salmonella 
dublin) but not in exactly the same genetic context. 
Colony characteristics 
Blood agar 
On blood agar, S. typhi and S. paratyphi usually produce non-hemolytic smooth white colonies.
MacConkey agar 
On MacConkey agar, salmonellae produce lactose non-fermenting smooth colonies.
Salmonella – Shigella (SS)agar 
On  SS  agar,  salmonellae  usually  produce lactose  non-fermenting colonies  with black centres 
(except S. paratyphi A, whose colonies do not have black centres).
Desoxycholate agar 
On desoxycholate agar,  salmonellae produce lactose non-fermenting colonies with black  centres 
(except S. paratyphi A, whose colonies do not have black centres).
Xylose-lysine-desoxycholate agar 
On xylose-desoxycholate  agar,  salmonellae  produce transparent  red colonies with black  centres 
(except S. paratyphi A, whose colonies do not have black centres).
Hektoen enteric agar 
On hektoen enteric  agar,  salmonellae  produce transparent  green colonies  with black  centres 
(except S. paratyphi A, whose colonies do not have black centres).
Bismuth sulfite agar 
On this medium, salmonellae produce black colonies.
Biochemical identification
Suspected colonies obtained on the above media are screened by means of the following 
media/tests:
Organism
Kliger's iron agar
Slant Butt H2S Gas
Motility Indole Urea Citrate
S. typhi Alk Acid Wk+ - + - - -
S. paratyphi A Ald Acid - + + - - -
Other  Salmonella 
spp.
Alk Acid V V + _ _ V
E. coli Acid Acid - + + + - -
Klebsiella spp. Acid Acid _ ++ _ V + +
Citrobacter spp. V Acid +++ + + V - +
Proteus spp. Alk Acid + + + V ++ V
The production of acid turns the agar yellow. For the slant this denotes lactose fermentation 
and for the butt this denotes glucose fermentation.
Alk = alkaline, Wk = weak, V= variable result.
Serological identification of Salmonella
Salmonellae can be characterized by their somatic (O) and flagellar (H) antigens, the latter 
existing in some serotypes in phases 1 and 2. Some salmonellae also have an envelop antigen 
called Vi (virulence). The O antigen is usually determined by means of the slide agglutination test 
with  group-specific  antiserum followed by  agglutination  with  factor  antiserum. H antigen is 
usually determined by means of the tube agglutination test.
Transmission
Humans are the only natural host and reservoir. The infection is transmitted by ingestion of 
food or water contaminated with faeces. Ice cream is recognized as a significant risk factor for the 
transmission of typhoid fever. Shellfish taken from contaminated water and raw fruit and vegetables 
fertilized with sewage, have been sources of past outbreaks.  The highest incidence occurs where 
water supply serving large populations is contaminated with faeces. Epidemiological data suggest 
that  waterborne  transmission  of  S.  typhi  usually  involves  small  inocula,  whereas  food  borne 
transmission is associated with large inocula and high attack rates over short periods. The inoculum 
size and the type of vehicle in which the organisms are ingested greatly influence both the attack 
rate and the incubation period. In volunteers who ingested 109 and 108 pathogenic S. typhi in 45 
ml of skimmed milk, clinical illness appeared in 98% and 89% respectively.  Doses of 105 caused 
typhoid  fever  in  28% to 55% of  volunteers,  whereas  none  of  14 persons who ingested 103 
organisms  developed  clinical  illness.  Although  it  is  widely  believed  that  Salmonella  is 
transmitted via the oral route, the transmission of S. typhimurium via the respiratory route 
has been demonstrated in a mouse model.
Family  studies  were  conducted  in  Santiago,  Chile,  during  an  era  of  high  typhoid 
endemicity in order to ascertain whether chronic carriers were significantly more  frequent in 
households where there were index cases of children with typhoid fever than in matched control 
households. . It was concluded that chronic carriers in households did not play an important role in 
transmission. In  developed  countries,  on the  other  hand,  typhoid is  transmitted when chronic 
carriers contaminate food as a consequence of unsatisfactory food-related hygiene practices.
Pathogenesis
During an acute infection, S. typhi multiplies in mononuclear phagocytic cells before being 
released into the bloodstream. After ingestion in food or water, typhoid organisms pass through the 
pylorus and reach the small intestine. They rapidly penetrate the  mucosal epithelium via either 
microfold cells or enterocytes and arrive in the lamina propria, where they rapidly elicit an influx of 
macrophages that ingest the bacilli  but do not generally kill them. Some bacilli remain within 
macrophages of  the  small  intestinal  lymphoid  tissue.  Other  typhoid  bacilli  are  drained  into 
mesenteric lymph nodes where there is further multiplication and ingestion by macrophages. It is 
believed  that  typhoid  bacilli  reach  the  bloodstream  principally  by  lymph  drainage  from 
mesenteric nodes,  after which they enter the thoracic duct and then the general circulation. As a 
result of this silent primary bacteraemia the pathogen reaches an intracellular haven within 24 
hours after ingestion throughout the organs of the reticuloendothelial system (spleen,  liver, bone 
marrow, etc.), where it resides during the incubation period, usually of 8 to 14 days. The incubation 
period in a particular individual depends on the quantity of  inoculum, i.e. it  decreases as the 
quantity of inoculum increases, and on host factors.  Incubation periods ranging from 3 days to 
more than 60 days have been reported. Clinical illness is accompanied by a fairly sustained but 
low level of secondary bacteraemia (~1—10 bacteria per ml of blood).
Clinical features
The clinical presentation of typhoid fever varies from a mild illness with low-grade  fever, 
malaise, and slight dry cough to a severe clinical picture with abdominal discomfort  and multiple 
complications. Many factors influence the severity and overall clinical outcome of the infection. 
They include the duration of illness before the initiation of appropriate therapy, the choice of 
antimicrobial treatment, age, the previous exposure  or vaccination history, the virulence of the 
bacterial strain, the quantity of inoculum  ingested, host factors (e.g. HLA type, AIDS or other 
immunosuppression) and whether the individual was taking other medications such as H2 blockers or 
antacids to diminish gastric acid. Patients who are infected with HIV are at significantly increased 
risk of clinical infection with S. typhi and S. paratyphi 4. Evidence of Helicobacter pylori infection 
also represents an increased risk of acquiring typhoid fever.
•Acute  non-complicated  disease:   Acute  typhoid  fever  is  characterized  by  prolonged
fever,  disturbances  of  bowel  function  (constipation  in  adults,  diarrhoea  in  children),
headache,  malaise  and  anorexia.  Bronchitic  cough  is  common  in  the  early  stage  of
the  illness.  During  the  period  of  fever,  up  to  25%  of  patients  show  exanthem  (rose
spots) on the chest, abdomen and back.
•Complicated  disease:   Acute  typhoid  fever  may  be  severe.  Depending  on  the  clinical
setting  and  the  quality  of  available  medical  care,  up  to  10%  of  typhoid  patients
may  develop  serious  complications.  Since  the  gut-associated  lymphoid  tissue
exhibits  prominent  pathology,  the  presence  of  occult  blood  is  a  common  finding
in  the  stool  of  10-20%  of  patients  and  up  to  3%  may  have  melena.  Intestinal
perforation  has  also  been  reported  in  up  to  3%  of  hospitalized  cases.  Abdominal
discomfort  develops  and  increases.  It  is  often  restricted  to  the  right  lower  quadrant
but  may  be  diffuse.  The  symptoms  and  signs  of  intestinal  perforation  and  peritonitis
sometimes  follow,  accompanied  by  a  sudden  rise  in  pulse  rate,  hypotension,  marked
abdominal  tenderness,  rebound  tenderness  and  guarding,  and  subsequent
abdominal  rigidity.  A  rising  white  blood  cell  count  with  a  left  shift  and  free  air  on
abdominal radiographs are usually seen.
Altered mental status in typhoid patients has been associated with a high case-fatality rate. 
Such  patients  generally  have  delirium or  obtundation,  rarely  with  coma.  Typhoid  meningitis, 
encephalomyelitis,  Guillain-Barré  syndrome,  cranial  or  peripheral  neuritis,  and  psychotic 
symptoms, although rare, have been reported. Other serious complications documented with 
typhoid fever include haemorrhages (causing rapid death in some patients), hepatitis, myocarditis, 
pneumonia,  disseminated  intravascular  coagulation,  thrombocytopenia  and  haemolytic  uraemic 
syndrome. In the pre-antibiotic  era, which had a different clinical picture, if patients did not die 
with  peritonitis  or  intestinal  haemorrhage,  15% of  typhoid  fever  cases  died  with  prolonged 
persistent  fever and diseases for no clear reason. Patients may also experience genitourinary tract 
manifestations or relapse, and/or a chronic carrier state may develop.
Diagnosis of typhoid fever
The definitive diagnosis of typhoid fever depends on the isolation of S. typhi from blood, 
bone marrow or a specific anatomical lesion. The presence of clinical symptoms characteristic of 
typhoid fever or the detection of a specific antibody response is suggestive of typhoid fever but 
not definitive. Blood culture is the mainstay of the diagnosis of this disease.
Although ox bile medium (Oxgall) is  recommended for enteric fever pathogens  (S. 
typhi  and  S.  paratyphi),  only  these  pathogens  can  be  grown  on  it.  In  a  general  diagnostic 
laboratory, therefore where other pathogens are suspected, a general blood culture medium should 
be used. More than 80% of patients with typhoid fever have the causative organism in their blood. 
A failure to isolate the organism may be caused by several factors: (i) the limitations of laboratory 
media 5; (ii) the presence of antibiotics 6; (iii) the volume of the specimen cultured 7; or (iv) the 
time of collection, patients with a history of fever for 7 to 10 days being more likely than others to 
have a positive blood culture. Bone marrow aspirate culture is the gold standard for the diagnosis of 
typhoid fever 8, 9, 10 and is particularly valuable for patients who have been previously treated, who 
have a long history of illness and for whom  there has been a negative blood culture with the 
recommended volume of blood. Duodenal aspirate culture has also proved highly satisfactory as a 
diagnostic test but has not found widespread acceptance because of poor tolerance of duodenal 
aspiration, particularly in children.
If a bacteriology laboratory is not available on site, clinical specimens for culture can  be 
transported to a main laboratory for processing. For blood culture it is essential to inoculate media 
at  the  time  of  drawing  blood.  For  other  specimens  it  is  advisable  to  make  the  time  of 
transportation  to  the  laboratory  as  short  as  possible.  It  is  more  important  to  process  the 
specimens quickly than to keep them cold. Once they have been inoculated, blood culture bottles 
should not be kept cold. They should be incubated at 37°C or, in tropical countries, left at room 
temperature, before being processed in the laboratory.
The volume of blood cultured is one of the most important factors in the isolation of  S. 
typhi from typhoid patients, 10-15 ml should be taken from schoolchildren and adults in order to 
achieve optimal isolation rates; 2-4 ml are required from toddlers and preschool children 7. This is 
because  children  have  higher  levels  of  bacteraemia  than  adults.  In  some  regions  it  may  be 
impossible to collect such large volumes of blood and so alternative diagnostic methods may be 
necessary for cases in which blood cultures are negative. Because reducing the blood volume reduces 
the sensitivity of the blood culture, however an effort should be made to draw sufficient blood if at 
all possible. Blood should be drawn by means of a sterile technique of venous puncture and should 
be inoculated immediately into a blood culture bottle with the syringe that has been used for 
collection.
The optimum ratio of the volume of blood to traditional culture broth should be 1 to 10 or 
more (e.g. 1:12).  In general, if 5 ml of blood are drawn they should be inoculated into 45 ml or 
more of broth. If 10-15 ml of blood are drawn the specimen can be divided into equal aliquots and 
inoculated into two or more blood culture bottles. This allows the use of standard blood culture 
bottles of 50 ml. For small children the volume of blood drawn can be reduced but should still be 
inoculated into 45 ml of culture broth. The blood culture bottle should then be transported to the 
main laboratory at ambient temperature (15°C to 40°C) as indicated above. Blood cultures should 
not be stored or transported at low temperatures. If the ambient temperature is below 15°C it is 
advisable to transport blood cultures in an incubator. In the laboratory, blood culture bottles should 
be incubated at 37°C and checked for turbidity, gas formation and other evidence of growth after 
1, 2, 3 and 7 days. For days 1, 2 and 3, only bottles showing signs of positive growth are cultured 
on agar plates. On day 7 all bottles should be subcultured before being discarded as negative.
A typical blood culture bottle contains 45 ml of tryptic soy broth or brain heart infusion broth. 
These are inoculated with 5 ml of fresh blood and incubated at 37°C. Negatives should be kept for at 
least seven days. Because S. typhi is not the only bacterial pathogen found in blood, subculturing is 
performed on days 1, 2, 3 and 7 on non-selective agar. The best agar is blood agar (horse or sheep 
blood) as this allows the growth of most  bacterial pathogens. If blood agar is not available, 
nutrient agar can be used in combination with MacConkey agar. In some laboratories the use of 
MacConkey agar  alone is preferred as this allows the growth of only bile-tolerant bacteria 
such as S. typhi  and does not allow the growth of many gram-positive contaminants.  The 
contamination of blood cultures reduces isolation rates for S. typhi and should be prevented as far 
as possible. For suspected typhoid fever, subculture plates should be incubated at 37°C for 
18-24 hours in an aerobic incubator.
The  identification  of  colonies  as  S.  typhi  is  straightforward  if  reagents  of  satisfactory 
quality  are available.  Colonies from solid media can be used for  agglutination with  specific 
antisera.  Several  salmonellae  may  share  the  same  antigenic  structure.  Consequently, 
confirmation by means of biochemical tests is always necessary.
Antimicrobial susceptibility test for typhoid fever organisms
Antimicrobial susceptibility testing is crucial for the guidance of clinical management. 
Isolates from many parts of the world are now multidrug-resistant (MDR). Isolates are usually 
resistant  to  ampicillin,  chloramphenicol,  sulfonamide,  trimethoprim,  streptomycin  and 
tetracycline.  Alternative  drugs  that  are  used  for  treatment  include:  fluoroquinolones  (e.g. 
ciprofloxacin), third-generation cephalosporins (e.g. ceftriaxone, cefotaxime), a monobactum 
beta-lactam (aztreonam) and a macrolide (azithromycin). Even though resistance to the first 
two  has  been  noted  they  nevertheless  remain  useful  11.  Reduced  susceptibility  to 
fluoroquinolones is indicated by in vitro resistance to nalidixic acid 12.
Felix-Widal test
This test measures agglutinating antibody levels against O and H antigens. The levels are 
measured by using doubling dilutions of sera in large test tubes. Usually O antibodies appear on days 
6-8 and H antibodies on days 10-12 after the onset of the disease. The test is usually performed 
on an acute serum (at first contact with the patient). A convalescent serum should preferably also 
be collected so that paired titrations can be performed. In practice, however, this is often difficult. At 
least 1 ml of blood should be collected each time in order to have a sufficient amount of serum. In 
exceptional circumstances the test can be performed on plasma without any adverse effect on the 
result.
The test has only moderate sensitivity and specificity. It can be negative in up to 30% of 
culture-proven cases of typhoid fever.  This may be because of prior antibiotic therapy  that  has 
blunted the antibody response. On the other hand, S. typhi shares O and H antigens with other 
Salmonella  serotypes and has cross-reacting epitopes with other  Enterobacteriacae, and this can 
lead to false-positive results. Such results may also occur in other clinical conditions, e.g. malaria, 
typhus, bacteraemia caused by other organisms, and cirrhosis. In areas of endemicity there is often 
a low background level of antibodies in the normal population. Determining an appropriate cut-off 
for a positive result can be difficult since it varies between areas and between times in given 
areas.
It  is  therefore  important  to  establish the antibody level  in the  normal  population in  a 
particular locality in order to determine a threshold above which the antibody titre is considered 
significant. This is particularly important if, as usually happens, a single acute sample is available 
for testing. If paired sera are available a fourfold rise in the antibody titre between convalescent 
and acute sera is diagnostic. Quality control of  the test is achieved by running a standard serum 
with a known antibody titre in parallel in each batch of assays. The variations in the standard serum 
should not exceed one tube, i.e. double dilution.
Despite these limitations the test may be useful, particularly in areas that cannot afford the 
more expensive diagnostic methods. This is acceptable so long as the results are interpreted with 
care in accordance with appropriate local cut-off values for the determination of positivity. This 
test is unnecessary if the diagnosis has already been confirmed by the isolation of S. typhi from a 
sterile site.
IDL Tubex® test
The Tubex® test is simple (essentially a one-step test) and rapid (taking approximately two 
minutes).  It  exploits  the  simplicity  and  user-friendliness  of  the  Widal  and  the  slide  latex 
agglutination  tests  but  uses  the  separation  of  coloured  particles  in  solution  to  improve 
resolution and sensitivity. Specificity is improved by means of an inhibition assay format and by 
detecting antibodies to a single antigen in S. typhi only. A positive result given by Tubex® invariably 
suggests a Salmonella infection. Infections caused by other serotypes including S. paratyphi A give 
negative results. Tubex® has not been evaluated extensively but several trials are being planned. In 
a preliminary study involving stored sera the test performed better than the Widal test in  both 
sensitivity and specificity 13.
Typhidot® test
This test makes use of the 50 kD antigen to detect specific IgM and IgG antibodies to S. 
typhi. It has undergone full-scale multinational clinical evaluation of its diagnostic value. This dot EIA 
test offers simplicity, speed, specificity (75%), economy, early diagnosis, sensitivity (95%) and high 
negative and positive predictive values. The detection of IgM reveals acute typhoid in the early 
phase of infection, while the detection of both IgG and IgM suggests acute typhoid in the middle 
phase  of  infection.  In  order  to  increase  diagnostic  accuracy  the  original  Typhidot®  test  was 
modified by inactivating total IgG in the serum sample. Studies with the modified test, Typhidot-
M®, have shown that  inactivation of IgG removes competitive binding and allow access of the 
antigen to the specific IgM when it is present. The detection of specific IgM within three hours 
suggests acute typhoid infection. Evaluations of Typhidot® and Typhidot-M® in clinical  settings 
showed that they performed better than the Widal test and the culture method 14.
In  laboratory diagnoses of typhoid fever the method used as the gold standard should 
approach 100% in sensitivity, specificity and positive and negative predictive values.  Evaluation 
studies have shown that Typhidot-M® is superior to the culture method. Although culture remains 
the gold standard it cannot match Typhidot-M® in sensitivity (>93%), negative predictive value and 
speed. Typhidot-M® can replace the Widal test when used in conjunction with the culture method 
for the rapid and  accurate diagnosis of typhoid fever. The high negative predictive value of the test 
suggests that Typhidot-M® would be useful in areas of high endemicity.
IgM dipstick test
The typhoid IgM dipstick assay is designed for the serodiagnosis of typhoid fever through 
the detection of S. typhi-specific IgM antibodies in serum or whole blood samples. The dipstick 
test provides a rapid and simple alternative for the diagnosis of typhoid fever, particularly in 
situations where culture facilities are not available.  The assay can be performed by people 
without  formal  training  and  in  the  absence  of  specialized  equipment.  Specific  antibodies 
usually appear a week after the onset of symptoms and signs. This should kept in mind when a 
negative serological test result is being interpreted. 
Drug resistance
There  are  two  categories  of  drug  resistance:  resistance  to  antibiotics  such  as 
chloramphenicol, ampicillin and trimethoprim-sulfamethoxazole (MDR strains) and resistance 
to the fluoroquinolone drugs. Resistance to the fluoroquinolones may be total or partial. The 
so-called nalidixic-acid-resistant  S. typhi  (NARST) is a  marker of reduced susceptibility to 
fluoroquinolones compared with nalidixic-acid-sensitive strains. Nalidixic acid itself is never 
used for the treatment of typhoid. These isolates are susceptible to fluoroquinolones in disc 
sensitivity testing according to current guidelines. However, the clinical response to treatment 
with  fluoroquinolones  of  nalidixic-acid-resistant  strains  is  significantly  worse  than  with 
nalidixic-acid-senstive strains. There is a significant number of MDR strains from the Indian 
subcontinent and some other Asian countries (not Indonesia). S. typhi has recently emerged as 
a problem in Kenya. Nalidixic-acid-resistant strains are now endemic in many areas of Viet 
Nam and have  also  been  reported  from the  Indian  subcontinent  and  Tajikistan.  There  are 
disturbing recent reports of the emergence of fluorquinolone-resistant isolates in various parts 
of Asia and there have been a few reports of resistance to third-generation cephalopsorins in 
the same region. Reassuringly, however, many of these reports are coupled with evidence of 
the re-emergence of sensitive isolates in the same regions.
Treatment of typhoid fever
General management
Supportive measures are important in the management of typhoid fever, such as oral or 
intravenous hydration, the use of antipyretics, and appropriate nutrition and blood transfusions 
if indicated. More than 90% of patients can be managed at home with oral antibiotics, reliable 
care and close medical follow-up for complications or failure to respond to therapy. However, 
patients  with  persistent  vomiting,  severe  diarrhoea  and  abdominal  distension  may  require 
hospitalization and parenteral antibiotic therapy.
Antimicrobial therapy
Efficacy,  availability  and  cost  are  important  criteria  for  the  selection  of  first-line 
antibiotics to be used in developing countries
The fluoroquinolones are widely regarded as optimal for the treatment of typhoid fever 
in adults  15.  Evidence from various settings in Asia indicates that  the fluoroquinolones are 
equally effective in the treatment of typhoid fever in children
However, the emergence of MDR strains has reduced the choice of antibiotics in many areas. 
Table 1 outlines the treatment strategies for uncomplicated typhoid.
Treatment of uncomplicated typhoid fever
Optimal therapy Alternative effective drugs
Susceptibility Antibiotic
Daily 
dose 
mg/kg
Days Antibiotic Daily 
dose 
mg/kg
Days
Fully sensitive Fluoroquinolone
e.g. ofloxacin or 
ciprofloxacin
15 5-7a Chloramphenicol
Amoxicillin
50-75
75-100
14-21
14
Multidrug 
resistance
Fluoroquinolone
or cefixime
15
15-20
5-7
7-14
Azithromycin
Cefixime
8-10
15-20
7
7-14
Quinolone 
resistanceb
Azithromycin
or ceftriaxone
8-10
75
7
10-14
Cefixime 20 7-14
a    Three-day courses are also effective and are particularly so in epidemic containment.
b The  optimum  treatment  for  quinolone-resistant  typhoid  fever  has  not  been  determined. 
Azithromycin,  the  third-generation  cephalosporins,  or  a  10-14  day  course  of  high-dose 
fluoroquinolones, is effective. Combinations of these are now being evaluated.
The  available  fluoroquinolones  (ofloxacin,  ciprofloxacin,  fleroxacin,  pefloxacin)  are 
highly  active  and  equivalent  in  efficacy  (with  the  exception  of  norfloxacin  which  has 
inadequate oral bioavailability and should not be used in typhoid fever).
The  fluoroquinolone  drugs  are  generally  very  well  tolerated.  However,  in  some 
countries  the  use  of  fluoroquinolones  is  relatively  contraindicated  in  children  because  of 
concerns that they may cause articular damage. These agents are not registered for routine use 
in children. The concerns have arisen because of evidence of articular damage in growing, 
weight-bearing joints in beagles 16. There is now extensive experience in the use of these drugs 
in  large  numbers  of  children  with  a  variety  of  conditions,  often  with  long-term follow-up 
(cystic  fibrosis,  typhoid)  and  in  the  extensive  use  of  short  courses  of  fluoroquinolones  in 
children for the treatment of both typhoid fever and bacillary dysentery 17. Their considerable 
benefits,  particularly  in areas  where  there are no affordable oral  alternatives,  outweigh the 
putative risk. The only known articular side-effect is Achilles tendon rupture in patients who 
are also taking corticosteroids, and this has been reported only rarely.
Ciprofloxacin,  ofloxacin,  pefloxacin  and  fleroxacin  have  generally  proved  effective. 
There is no evidence of the superiority of any particular fluoroquinolone. Nalidixic acid and 
norfloxacin do not achieve adequate blood concentrations after oral administration and should 
not be used. 
Chloramphenicol,  despite the risk of agranulocytosis in 1 per 10000 patients,  is  still 
widely prescribed in developing countries for the treatment of typhoid fever. The disadvantages 
of  using  chloramphenicol  include  a  relatively  high  rate  of  relapse  (5-7%),  long  treatment 
courses (14 days) and the frequent development of a carrier state in adults. The recommended 
dosage is 50-75 mg per kg per day for 14 days divided into four doses per day, or for at least 
five to seven days after defervescence. The usual adult dose is 500 mg given four times a day. 
Oral  administration  gives  slightly  greater  bioavailability  than  intramuscular  (i.m.)  or 
intravenous (i.v.) administration of the succinate salt.
Ampicillin and amoxicillin are used at 50 to 100 mg per kg per day orally, i.m. or i.v., 
divided into three or four doses. No benefit has been reported to result from the addition of 
clavulanic acid to amoxicillin.
Trimethoprim-sulfamethoxazole, (TMP-SMZ) can be used orally or i.v. in adults at a 
dose of 160 mg TMP plus 800 mg SMZ twice daily or in children at 4 mg TMP per kg and 20 
mg SMZ per kg for 14 days.
Of  the  third-generation  cephalosporins,  oral  cefixime (15-20 mg per  kg per  day  for 
adults, 100-200 mg twice daily) has been widely used in children in a variety of geographical 
settings and found to be satisfactory. 
Recent data on the use of azithromycin in children indicate that it may be safely given as 
an alternative agent for the treatment of uncomplicated typhoid fever. Azithromycin in a dose 
of 500 mg (10 mg/kg) given once daily for seven days has proved effective in the treatment of 
typhoid fever in adults and children with defervescence times similar to those reported for 
chloramphenicol. A dose of 1 g per day for five days was also effective in adults 15.
If intravenous antibiotics are required, i.v. cephalosporins can be given in the following 
doses: ceftriaxone, 50-75 mg per kg per day (2-4 g per day for adults) in one or two doses; 
cefotaxime, 40-80 mg per kg per day (2-4 g per day for adults) in two or three doses; and 
cefoperazone 50-100 mg per kg per day (2-4 g per day for adults) in two doses. Ciprofloxacin, 
ofloxacin and pefloxacin are also available for i.v. use.
Most of the data from randomized controlled trials relate to patients treated in regions of 
endemicity.  Knowledge  of  the  antibiotic  sensitivity  of  the  infecting  strain  is  crucial  in 
determining drug choice. If no culture is available, knowledge of likely sensitivity as indicated 
by the available global data may be useful.
The evidence suggests that the fluoroquinolones are the optimal choice for the treatment 
of typhoid fever in adults and that they may also be used in children. The recent emergence of 
resistance to fluoroquinolones, however, suggests that their widespread and indiscriminate use 
in primary care settings should be restricted. In areas of the world where the fluoroquinolones 
are not available or not registered for public health use and where the bacterium is still fully 
sensitive  to  traditonal  first-line  drugs  (chloramphenicol,  amoxicillin  or  trimethoprim-
sulfamethoxazole)  these  remain  appropriate  for  the  treatment  of  typhoid  fever.  They  are 
inexpensive, widely available and rarely associated with side-effects.
Management of complications
Both outpatients and inpatients with typhoid fever should be closely monitored for the 
development  of  complications.  Timely  intervention  can  prevent  or  reduce  morbidity  and 
mortality.  The parenteral  fluoroquinolones are probably the antibiotics of choice for severe 
infections  but  there  have  been  no  randomized  antibiotic  trials.  In  severe  typhoid  the 
fluoroquinolones are given for a minimum of 10 days. Typhoid fever patients with changes in 
mental  status,  characterized  by  delirium,  obtundation  and  stupor,  should  be  immediately 
evaluated for meningitis by examination of the cerebrospinal fluid. If the findings are normal 
and typhoid meningitis is suspected, adults and children should immediately be treated with 
high-dose  intravenous  dexamethasone  in  addition  to  antimicrobials  18.  If  dexamethasone  is 
given in an initial dose of 3 mg/kg by slow i.v. infusion over 30 minutes and if, after six hours, 
1 mg/kg is administered and subsequently repeated at six-hourly intervals  on seven further 
occasions,  mortality  can  be  reduced  by  some  80-90%  in  these  high-risk  patients. 
Hydrocortisone in  a lower  dose  is  not  effective.  High-dose steroid treatment  can be  given 
before the results of typhoid blood cultures are available if other causes of severe disease are 
unlikely.
Treatment of severe typhoid fever
Optimal parenteral drug Alternative effective parenteral drug
Susceptibility Antibiotic Daily 
dose 
mg/kg
Days Antibiotic Daily 
dose 
mg/kg
Days
Fully sensitive Fluoroquinolone 
e.g. ofloxacin
15 10-14 Chloramphenicol 
Amoxicillin TMP-
SMX
100 
100 
8-40
14-21 
14
14
Multidrug 
resistant
Fluoroquinolone 15 10-14 Ceftriaxone or 
cefotaxime
60 
80
10-14
Quinolone 
resistant
Ceftriaxone or 
cefotaxime
60 
80
10-14 Fluoroquinolone 20 7-14
 Patients  with  intestinal  haemorrhage  need  intensive  care,  monitoring  and  blood 
transfusion.  Intervention  is  not  needed  unless  there  is  significant  blood  loss.  Surgical 
consultation  for  suspected  intestinal  perforation  is  indicated.  If  perforation  is  confirmed, 
surgical repair should not be delayed longer than six hours. Metronidazole and gentamicin or 
ceftriazone should be administered before and after surgery if a fluoroquinolone is not being 
used to  treat  leakage of  intestinal  bacteria  into the  abdominal  cavity.  Early  intervention  is 
crucial and mortality rates increase as the delay between perforation and surgery lengthens. 
Mortality rates vary between 10% and 32% 19.
Relapses  involving  acute  illness  occur  in  5-20%  of  typhoid  fever  cases  that  have 
apparently been treated successfully. A relapse is heralded by the return of fever soon after the 
completion of  antibiotic  treatment.  The clinical  manifestation is  frequently  milder  than the 
initial illness. Cultures should be obtained and standard treatment should be administered. In 
the event of a relapse the absence of schistosomiasis should be confirmed.
Management of carriers
An individual is considered to be a chronic carrier if he or she is asymptomatic and 
continues to have positive stool or rectal swab cultures for S. typhi a year following recovery 
from acute illness. Overall, some 1-5% of typhoid fever patients become chronic carriers. The 
rate of carriage is slightly higher among female patients,  patients  older than 50 years,  and 
patients with cholelithiasis or schistosomiasis. If cholelithiasis or schistosomiasis is present the 
patient probably requires cholecystectomy or antiparasitic medication in addition to antibiotics 
in order to achieve bacteriological cure. In order to eradicate S. typhi carriage, amoxicillin or 
ampicillin (100 mg per kg per day) plus probenecid  (1 g orally or 25 mg per kg for children) or 
TMP-SMZ (160 to 800 mg twice daily) is administered for six weeks; about 60% of persons 
treated with either regimen can be expected to have negative cultures on follow-up. Clearance 
of  up  to  80% of  chronic  carriers  can  be  achieved  with  the  administration  of  750  mg  of 
ciprofloxacin twice daily for 28 days or 400 mg of norfloxacin. Other quinolone drugs may 
yield similar results. Carriers should be excluded from any activities involving food preparation 
and  serving,  as  should  convalescent  patients  and  any  persons  with  possible  symptoms  of 
typhoid fever. Although it would be difficult for typhoid carriers in developing countries to 
follow this recommendation, food handlers should not resume their duties until they have had 
three negative stool cultures at least one month apart.
Vi antibody determination has been used as a screening technique to identify carriers 
among food handlers and in outbreak investigations. Vi antibodies are very high in chronic S. 
typhi carriers.
Prevention of typhoid fever
The major routes of transmission of typhoid fever are through drinking water or eating 
food contaminated with Salmonella typhi. Prevention is based on ensuring access to safe water 
and by promoting safe food handling practices. Health education is paramount to raise public 
awareness and induce behaviour change.
Safe water
Typhoid fever is a waterborne disease and the main preventive measure is to ensure 
access to safe water. The water needs to be of good quality and must be sufficient to supply all 
the community with enough drinking water as well as for all other domestic purposes such as 
cooking and washing.
Food safety
Contaminated food is another important vehicle for typhoid fever transmission.
Appropriate food handling and processing is paramount and the following basic hygiene 
measures must be implemented or reinforced during epidemics:
•washing hands with soap before preparing or eating food;
•avoiding raw food, shellfish, ice;
•eating only cooked and still hot food or re-heating it.
Typhoid can be transmitted by chronic  carriers  who do not apply satisfactory food-
related hygiene practices. These carriers should be excluded from any activities involving food 
preparation and serving. They should not resume their duties until they have had three negative 
stool cultures at least one month apart.
Sanitation
Proper  sanitation  contributes  to  reducing  the  risk  of  transmission  of  all  diarrhoeal 
pathogens including Salmonella typhi.
•Appropriate  facilities  for  human  waste  disposal  must  be  available  for  all  the
community. In an emergency, pit latrines can be quickly built.
•Collection and treatment of sewage, especially during the rainy season, must be implemented
•In areas where typhoid fever is known to be present, the use of human excreta as fertilizers 
must be discouraged.
Health education
Health education is paramount to raise public awareness on all  the above mentioned 
prevention measures. Health education messages for the vulnerable communities need to be 
adapted to local conditions and translated into local languages. In order to reach communities, 
all possible means of communication (e.g. media, schools, women's groups, religious groups) 
must be applied.
Community involvement is the cornerstone of behaviour change with regard to hygiene 
and for setting up and maintenance of the needed infrastructures.
In health facilities, all staff must be repeatedly educated about the need for :
•excellent personal hygiene at work;
•isolation measures for the patient;
•disinfection measure.
Vaccination
Currently available vaccines
The old parenteral killed whole-cell  vaccine was effective but produced strong side-
effects because of LPS. Two safe and effective vaccines are now licensed and available. One is 
based on defined subunit antigens, the other on whole-cell live attenuated bacteria.
The  first  of  these  vaccines,  containing  Vi  polysaccharide,  is  given  in  a  single  dose 
subcutaneous (s.c.) or i.m. Protection begins seven days after injection, maximum protection 
being reached 28 days after injection when the highest antibody concentration is obtained. The 
vaccine is approved for persons aged over two years. Revaccination is recommended every 
three years for travellers. 
The live oral vaccine Ty2la is available in enteric-coated capsule or liquid formulation. 
It should be taken in three doses two days apart on an empty stomach. It elicits protection as 
from 10-14 days after the third dose. It is approved for use in children aged at least 5 years. 
Travellers  should  be  revaccinated  annually.  The  protective  efficacy  of  the  enteric-coated 
capsule formulation seven years after the last dose is still 62% in areas where the disease is 
endemic;  the  corresponding  figure  for  the  liquid  formulation  is  70%.  Herd  immunity  was 
clearly demonstrated during field trials in Chile. Antibiotics should be avoided for seven days 
before or after the immunization series. 
Future vaccines
 Vi-rEPA  
A new Vi conjugate candidate vaccine bound to non-toxic recombinant  Pseudomonas 
aeruginosa  exotoxin A (rEPA) has enhanced immunogenicity in adults and in children aged 
5-14 years, and has induced a booster response in children aged 2-4 years. 
S. paratyphi  A causes the second commonest enteric fever in Asia. The TAB vaccine, 
composed of  inactivated  Salmonella,  caused a  strong side-reaction.  A new  S.  paratyphi  A 
vaccine composed of the surface O-specific polysaccharide conjugated with tetanus toxoid was 
shown to be safe and immunogenic in Vietnamese adults, 108 teenagers and 110 children aged 
2-4 years. 
Other candidates
Three  live  attenuated  candidate  vaccines  are  currently  being  evaluated.  Each  is 
administered as a single oral dose. CVD 908-htrA is an S. typhi strain with a mutation deletion 
in the  htrA gene; a derivative strain, CVD 909, was prepared in order to produce Vi antigen 
according to constitutive expression. The second candidate is an S. typhi Ty2 strain with triple 
mutation deletion in the cya, crp and cdt genes. The third is a derivative of an  S. typhi  Ty2 
strain with a double mutation deletion in genes phoP and phoQ.
Recommendations on vaccine use
The occurrence of S. typhi strains that are resistant to fluoroquinolones emphasizes the 
need  to  use  safe  and  effective  vaccines  to  prevent  typhoid  fever.  WHO  recommends 
vaccination for people travelling in high-risk areas where the disease is endemic. People living 
in such areas, people in refugee camps, microbiologists, sewage workers and children should 
be the target groups for vaccination.
In routine immunization, therefore, the use of the available typhoid vaccines should be 
considered in areas where typhoid fever is endemic in children aged over two years. Either Vi 
or  Ty21a  vaccine  should  be  used.  The  Vi  vaccine  is  recommended  for  use  in  immuno-
compromised hosts.
Literature review
 Raghu Raman, et al 20 from Banglore reported on the clinical profile and therapy 
in enteric fever in 1992. 90 consecutive culture positive enteric fever cases were studied. 
The clinical profile and the resistance patterns are noted. They found MDRST incidence 
to  be  55% and certain  clinical  features  like  fever  >104o C,  toxemia,  hepatomegaly, 
abdominal  distension  were  significantly  more  in  MDR  group,  though  the  age  and 
duration of fever at admission were not significantly different between two groups. They 
concluded that characteristic clinical features in MDRST infection as seen in this study 
should be a pointer to the clinician to suspect and choose appropriate therapy.
           S.Mishra, et al 21 studied the clinical profile of multidrug resistant typhoid fever 
cases admitted in a hospital  in New Delhi in 1990.  Out of 214 cases admitted with 
clinical diagnosis of enteric fever, 50 were blood culture positive and were included in 
the study. 39 out of this 50(78%) were MDR. Children <2 years are found exclusively in 
MDRTF  group  and  complication  like  typhoid  encephalopathy,  hepatitis, 
bronchopneumonia,  myocarditis  and  pleural  effusion  were  some  of  the  serious 
complications observed exclusively in MDRTF.
             65 blood culture proven cases of typhoid fever were studied by A Sharma et al 22 
from Rohtak and 64.6% were MDR. In patients with MDR, the age was higher (9.8 vs. 
6.8). They found that there was no difference in the clinical features at the onset between 
the two groups though the incidence of complications such as shock, encephalopathy, 
myocarditis and gastric hemorrhage were more frequent in MDR group compared to 
chlormphenicol sensitive group
          U.Madhulika, et al 23 reported the antimicrobial susceptibility pattern of S.typhi 
isolated in Pondicherry between January 2002 to November 2003. Blood culture was 
done for 1296 patients suspected to have enteric fever and 157 isolates were obtained 
and included in the study. They used nalidixic acid susceptibility as a screening test for 
reduces susceptibility to ciprofloxacin. They found a slight decrease in the occurrence of 
MDRST compared to an earlier study, and an increase in resistance to fluroquinolones. 
They concluded that first line antibiotics may still have a role to play in typhoid fever 
and ceftriaxone emerges as the sole defence against NARST strains 
          Similar study reporting the sensitively pattern of salmonella serotypes in Northern 
India between  1997 to 2001 was done by vikas Gowtam et al 24 from Rohtak. Among 
the 6956 cultures done, they studied 60 randomly isolated strains and found an increase 
in occurrence of MDRST and a decrease in susceptibility to ciprofloxacin. They found 
reemergence of chloramphenicol sensitivity at the extent of 90% and they recommended 
that  sensitivity  pattern  of  causative  organism  must  be  sought  before  instituting 
appropriate therapy to prevent further emergence of drug resistance.
P.B.Koul, et al25 form New Delhi studied 48 consecutive culture proven typhoid 
cases, who had not received any antibiotics prior to admission. Seventy two point eight 
percent  of  blood  culture  positive  S.typhi  were  resistant  to  chloramphenicol.  Of  the 
chloramphenicol resistant strains, 48.5% were resistant to cotrimoxazole and 31.4% to 
cotrimoxazole  and  amoxicillin.  A  combination  of  cephalexin  and  gentamicin  was 
successfully used in management of these children. Incidence of shock, myocarditis and 
encephalopathy was higher among MDRST group.
Chandra  R,  et  al26 from pondicherry  studied  multidrug  resistant  enteric  fever 
cases.  A retrospective  review of  multidrug  resistant  typhoid fever  cases  admitted to 
paediatric  ward of  JIPMER hospital  was done.  Prolonged pyrexia,  chills  and rigors, 
toxaemia and tender hepatomegaly were striking features of  MDRST cases.  Positive 
blood  cultures  were  observed  even  after  weeks  of  antibiotic  therapy,  indicating 
persistent bacteremia. Ciprofloxacin was found to be best for MDRST in terms of rapid 
response and cost effectiveness. Cefotaxime has moderate efficacy.
Biswal N, et al27 from Pondicherry studied all  cases of enteric fever admitted 
between 1988 to 1992. They found there was gradual rise in number of admitted cases. 
CNS complications were noted more during 1991 and 1992.Other complications like 
myocarditis. GI bleed were noted in increasing number in 1991-92. Multidrug resistant 
cases were 46.3% in 1991 and 33.5% in 1992. There has been an increase in resistance 
of  S.typhi  to  commonly  used  to  drugs  like  ampicillin,  chloramphenicol  and 
cotrimoxazole.
Shorey H.S, et al  28 from Bombay studied an outbreak called ‘Dombivali fever’ 
started in March 1990 and spread to all over Bombay and adjoining areas. Later, it was 
proved to be resistant typhoid fever only. A very high isolation rate (215 isolates) in 
1990 as compared to be isolates in previous 2 years (i.e. in 1988 and 89) was observed. 
The incidence MDRST was very high (67.6%) in 1990, as compared to 6.2% in 1988 
and 23.3% in 1989. All strains tested in 1990 were sensitive to ciprofloxacin.
Holder K, et al29 studied 51 strains of s.typhi,  isolated during the outbreak of 
enteric fever in and around Calcutta,  in 1991. Forty strains were multidrug resistant 
including  chloramphenicol  and  all  these  strains  were  senstitive  to  cephalexin, 
gentamicin, furazolidone and ciprofloxacin. Widal test was done in all cases, but the 
result was inconclusive.
Walia M, et al30 in their retrospective study on current perspectives of enteric 
fever  analyzed blood culture-confirmed cases of enteric fever diagnosed at Safdarjang 
Hospital, New Delhi, India from January 2001 to December 2003. Of 377 blood culture-
positive cases, 80.6% were Salmonella typhi and 19.4% Salmonella paratyphi A; 21.7% 
were children aged under 5 years and 6.1% were under 2 years. A significant decline in 
MDRST was observed, from 21.9% in 2001 to 12.4% in 2003 (p=0.04). There was a 
significant increase in nalidixic acid-resistant Salmonella (NARST) from 56.9% in2001 
to 88.9% in 2003 (p=0.0001). NARST had a significantly longer fever defervescence 
time (7.7 v/s 4.7 days, p<0.001) and hospital stay (12.1 v/s 8.2 days, p<0.001),  and 
higher rates of complications (55.5% vs 24.0%, p=0.014) and mortality than nalidixic 
acid-sensitive  Salmonella  (NASS).  The  rate  of  isolation  of  MDRST  was  higher  in 
NARST than NASS (18.8% vs 7.3%, p=0.013)
Das U, et al31 studied  Multidrug resistant Salmonella typhi in Rourkela, Orissa. 
Out  of  5410  blood  samples  715  samples  were  positive  for  Salmonella  typhi.  The 
number of multidrug resistant strains of Salmonella typhi isolated constituted almost 
16.1% of the total isolates. In this study, chloramphenicol sensitivity was found to be 
quite  high  (86.5%)  and  ceftriaxone  showed  100%  sensitivity.  Resistance  to 
ciprofloxacin  was  found  to  be  2.5%  which  is  due  to  direct  consequence  of 
indiscriminate use of antibiotics, either singly or in combination.
Kabra SK et al32 studied Multidrug-resistant typhoid fever in Ahmedabad India. 
One hundred children (consecutive) with positive blood culture for Salmonella typhi 
were studied for clinical profile and complications.The common clinical features were 
fever (100%), vomiting (58%), abdominal pain (48%), cough (22%) and loose stools 
(14%)  and  the  Widal  test  was  positive  in  75%  patients.  Eighty  per  cent  of  the 
salmonella isolates were resistant to amoxycillin, chloramphenicol and co-trimoxazole 
drugs, but all were sensitive to ciprofloxacin and ceftriaxone. Forty patients developed 
complications:  encephalopathy  (18),  malena  (12),  haematemesis  (10),  epistaxis  (4), 
hepatitis  (4),  acalculous  cholecystitis  (4),  bowel  perforation  (3)  and  nephritis  (2). 
Complications  were  more  frequent  in  children  with  multidrug-resistant  typhoid.The 
final  antibiotic  required  to  render  the  children afebrile  included ciprofloxacin  (80), 
ceftriaxone,  amoxycillin  (4),  chloramphenicol  (4),  amoxycillin  and  gentamicin  (4), 
amoxycillin with chloramphenicol (2),  and furazolidone (2).The defervescence time 
was  least  with  ceftriaxone  and greatest  with  amoxycillin.  All  the  affected  children 
made a complete recovery.
                      
Kadhiravan T, et al33 studied the clinical and laboratory features, fever clearance 
time and complications prospectively  in  patients  with blood culture-proven typhoid 
fever,  treated  at  a  tertiary  care  hospital  in  north  India,  during  the  period  from 
November  2001  to  October  2003.  Susceptibility  to  amoxycillin,  co-trimoxazole, 
chloramphenicol, ciprofloxacin and ceftriaxone were tested by disc diffusion method. 
During a two-year period, 60 patients (age [mean +/- SD]: 15 +/- 9 years; males: 40 
[67%]) were studied. All isolates were sensitive to ciprofloxacin and ceftriaxone by 
disc diffusion. However, 11 patients had clinical failure of fluoroquinolone therapy. 
Infections with NARST isolates (47 [78%]) were significantly associated with longer 
duration of fever at presentation (median [IQR] 10 [7-15] vs. 4 [3-6] days; P = 0.000), 
higher frequency of hepatomegaly (57% vs. 15%; P = 0.021), higher levels of aspartate 
aminotransferase (121 [66-235] vs. 73 [44-119] IU/L; P = 0.033), and increased MIC 
of ciprofloxacin (0.37 +/- 0.21 vs. 0.17 +/- 0.14 microg/mL; P = 0.005), as compared to 
infections with nalidixic acid-susceptible isolates. All 11 patients with complications 
were infected with NARST isolates. Total duration of illness was significantly longer 
in patients who developed complications than in patients who did not (22 [14.8-32] vs. 
12 [9.3-20.3] days; P = 0.011). They concluded that typhoid fever caused by NARST 
infection is associated with poor clinical outcomes, probably due to delay in initiating 
appropriate  antibiotic  therapy.  Fluoroquinolone  breakpoints  for  S.  typhi  need  to  be 
redefined and fluoroquinolones should no longer be used as first-line therapy, if the 
prevalence of NARST is high.
  
Chande C, et al34 studied antimicrobial resistance pattern of Salmonella Typhi in 
central India.  A total of 54 isolates of Salmonella were recovered from 1468 blood 
samples of patients suspected to have enteric fever and admitted in the Government 
Medical College and Hospital,  Nagpur.  Antimicrobial susceptibility pattern of these 
isolates  was  studied  by  disc  diffusion  test.  Minimum  inhibitory  concentration  of 
chloramphenicol  was  determined  by  agar  dilution  method.  Of  54  isolates  of 
Salmonella,  51(94%)  were  S.  Typhi  and  3  (6%)  were  S.  paratyphi  A  serotype. 
Multidrug resistance was observed in 12 (22%) strains of S. Typhi. Thirty five (68%) 
strains  were  sensitive  to  chloramphenicol,  ampicillin,  gentamicin,  cotrimoxazole, 
cefotaxime and ciprofloxacin. Resistance to two antibiotics was observed in 4 (8%) 
strains. Cefotaxime resistance was observed in one isolate and gentamycin resistance in 
two, while none of the isolates was found to be ciprofloxacin resistant. They concluded 
that multidrug resistance in S. Typhi has decreased from that reported in 1991 though 
there is a still a small percentage of strains which continue to be multidrug resistant.
STUDY JUSTIFICATION:
Enteric  fever  continues  to  be  a  major  public  health  problem  despite  the 
development of newer antibacterial drugs. Drug resistance among S.typhi is known from 
1950, when chloramphenicol resistance was first reported. However until 1986 enbloc 
resistance involving all the three first line drugs was limited to anecdotal case reports. 
The  1990s witnessed a  surge in  the  incidence  of  multi  drug  resistant  typhoid fever 
(MDRTF) and studies from India report an incidence between 10-93% 35,36,37,22 .
The present problem is the emergence of quinolone resistance in addition to multi 
drug  resistant  salmonella  typhi  (MDRST).   Multi  Drug  Resistance  is  defined  as 
resistance  to  all  the  first  line  drugs  namely  ampicillin,  chloramphenicol,  and 
cotrimoxazole.  Quinolone resistance is  determined by sensitivity  to nalidixic acid as 
suggested by WHO and these nalidixic acid resistant Salmonella typhi (NARST) implies 
Quinolone resistance to the clinician.
In  the  present  scenario  of  emergence  of  nalidixic  acid  (Quinolone)  resistant 
strains  in  addition  to  resistance  to  conventional  drugs  and  wide  variation  in 
susceptibility of S.typhi among different geographical  area,  it  is  essential to find the 
resistance patterns in each locality and hospital including the MDR strains and NARST. 
In addition by comparing the clinical features of MDRTF with sensitive strains, the risk 
factor for MDR can be identified and this will provide a clinical clue to the presence of 
MDR and thus aid in formulating appropriate guidelines for therapy of typhoid fever.

AIM 
           To study 
1. The prevalence and pattern of resistance in typhoid fever including MDRST and NARST 
2. Clinical  presentation  of  drug  resistant  typhoid  fever  and  risk  factors  for  multidrug 
resistance.     
METHODOLOGY
STUDY DESIGN: Descriptive study / Case control study
STUDY PLACE:  All medical wards of Institute of Child Health and Hospital for Children
STUDY PERIOD: February 2005 to August 2006
TARGET POPULATION: All children admitted with clinical suspicion of typhoid fever.
STUDY POPULATION: All children with fever (38oC and above) for atleast three days, with 
a  laboratory  confirmed positive  culture  of  S.typhi.(WHO definition for  confirmed cases  of 
typhoid fever) 38.
EXCLUSION  CRITERIA: Associated  infections  (mixed  infections)  like  UTI,  malaria, 
leptospirosis, prior antibiotic usage  
 SAMPLE SIZE: All those children who satisfy the inclusion criteria with in the study period. 
MANEUVRE
Suspected  cases  of  typhoid  fever  were  admitted  in  our  hospital  and  detailed 
history was taken including age, sex, duration of fever and associated symptoms. Also 
history  of  previous  treatment,  socio-economic  status  and  typhoid  immunization  was 
elicited.  Then  complete  physical  examination  was  performed  to  assess  the  general 
condition of the patient, nutritional status and temperature; and examination of systems 
was done. Significant hepatomegaly was considered to be present, only when the liver 
size is more than 3.5 cms in new born and 2 cms in children.
After that blood was drawn for investigations like Widal test, enteric culture; and 
also for other investigations to rule out other causes of fever (like smear for malarial 
parasite, MSAT, non-enteric culture). Urine routine examination and culture was done.
Blood for enteric culture was taken in Brain-Heart infusion (BHI) broth. One ml 
of blood was taken using sterile syringe / scalp vein set and put into 10ml of BHI broth 
to give an optimal dilution of 1:10.  Since blood contains substances that  inhibit  the 
growth of bacilli, it is essential that the broth be taken in sufficient quantity to provide at 
least four fold dilution of blood. Liquoid (Sodium polyethanol sulphonate) was added to 
BHI broth during its  preparation to counteract  the bactericidal  action of  blood.  BHI 
broth  was  kept  in  refrigerator  prior  to  use  to  avoid  bacterial  contamination.  Before 
adding blood, the BHI broth was brought down to normal temperature and blood was 
added. After adding blood, BHI broth was immediately transported to microbiology lab 
of  the  hospital.  If  it  was  not  possible,  as  in  night  times,  the  bottle  was  kept  in  the 
incubator and then transported to lab. This avoided bacterial overgrowth and enhanced 
the chances of positivity of salmonella typhi growth.
ENTERIC CULTURE
In the lab, BHI broth was incubated at 37OC in the incubator for 24hrs. Then 
subculture was done in MacConkey agar and salmonella shigella agar, which is a special 
media  for  S.typhi.  After  overnight  incubation  at  37OC,  the  pale  smooth,  nonlactose 
fermenting  colonies  were  looked  for.  If  present,  then  battery  of  tests  was  done  to 
confirm S.typhi growth. S.typhi has the following characters:
1. Motility by hanging drop: Motile
2. Bio-chemical characters
S.typhi  is  citrate  positive,  indole  and  urease  negative  and  ferments  glucose, 
mannitol and maltose, not sucrose and lactose.
3. Agglutination
A loopful of growth from the agar is  emulsified with saline and a loopful of 
typhoid ‘H’ and ‘O’ antiserum were added. Presence of agglutination indicates 
salmonella growth.
After  confirming the growth,  antibiotic  sensitivity  was done in Muller-Hinton 
agar,  using Kirby-Baur technique. A loopful of growth was taken from the agar and 
inoculated in peptone water; after 10 minutes, this peptone water was poured over the 
Muller-Hinton agar to cover its entire surface; the excess peptone water was poured into 
the bottle.
Then  antibiotic  discs  like  ampicillin,  chloramphenicol  and  ciprofloxacin  etc., 
were plated and incubated for 24 hrs at 37OC. Then zone of inhibition was measured and 
results were interpreted.
Culture negativity was declared only after seven days. Then the patients were 
observed  daily  for  clinical  improvement  in  the  form  of  cessation  of  fever  and 
improvement in the general  well  being. Also complications (due to disease or drug) 
were carefully watched for. If the patient becomes culture positive, then the antibiotics 
were decided according to sensitivity pattern. All the cases were observed daily till the 
time of discharge.
STATISTICAL ANALYSIS
            1. Proportion of MDRTF and NARST among culture proven typhoid fever was found.
2. To associate various features to drug resistance, univariate analysis was done to arrive 
at odds ratio (OR) with 95% confidence interval.
 3. To associate how far individual factors contribute independently for drug resistance, 
multi variate analysis was done.
RESULTS
Out of 186 samples of the enteric culture sent, 39 grew S.typhi with a culture positive rate of 
21%. Only those with culture proven typhoid fever were included in the study (WHO definition of 
confirmed cases of typhoid).
Culture 
positive
21%
Culture 
negative
79%

The following is the invitro antibiotic susceptibility pattern of the 39 cultures grown 
Tab 1 : Antibiotic susceptibility pattern among 39 culture positive cases
Sl 
No
Drug Sensitive Resistant
N = % N = %
1 Ampicillin 16 41 23 59
2 Chloramphenicol 22 56.4 17 43.6
3 Cotrimoxazole 10 25.6 29 74.4
4 Cefotaxime 30 76.9 9 23.1
5 Ceftriaxone 35 89.7 4 10.3
6 Nalidixic acid 31 79.4 8 20.6
7 Ciprofloxacin 31 79.4 8 20.6
8 Amikacin 34 87.2 5 12.8
Multidrug resistance is present when the isolates were resistant to all the three first line drugs 
namely ampicillin, chloramphenicol and cotrimoxazole. The isolates are considered drug sensitive if 
they are sensitive to at least one of these first line drugs. The incidence of multi-drug resistance 
(defined by resistance to all the first line drugs namely ampicillin, cotrimoxazole and chloramphenicol) 
and quinolone resistance was found to be
Incidence of multidrug resistance: 43.6% ( N = 17 )
Multidrug
resistance
sensitive 
Incidence of quinolone resistance: 20.5% (N = 8)
Quinolone
resistance
sensitive
The following is the demographic profile of the various cases included in the study 
Tab 2: demographic profile of the various cases included in the study
 
Total (N =39) MDR (N=17) Sensitive (N=22)
n % n % n %
Age
<5 years 19 48.7 12 70.6 7 31.8
> 5 years 20 51.3 5 29.4 15 68.2
Sex
Male 22 56.4 10 58.8 12 54.5
Female 17 43.6 7 41.2 10 45.5
Season
I 21 53.8 9 52.9 12 54.5
II 18 46.2 8 47.1 10 45.5
The following is the symptom profile of the multi-drug resistant and drug sensitive 
typhoid fever 
Tab 3: Clinical profile – symptoms 
Total (N 
=39)
MDR 
(N=17)
Sensitive 
(N=22)
n % n % n %
p-value
O.R. 95% C.I.
Age <5 years 19 48.7 12 70.6 7 31.8 0.02 5.1 1.1 , 26.3
Fever > 7 days 20 51.3 13 76.5 7 31.8 0.01 7.0 1.4 , 38.8
Chills/Rigor 13 33.3 6 35.3 7 31.8 0.82 1.2 0.2 , 5.5
Abdominal 
Symptoms 21 53.8 9 52.9 12 54.5 0.9 0.9 0.2 , 4.0
Respiratory 
Symptoms 20 51.3 12 70.6 8 36.4 0.08 3.3 0.7 , 15.2
CNS Symptoms 4 10.3 2 11.8 2 9.1 0.8 1.3 0.1 , 15.5
The following is the clinical profile - signs of the multi-drug resistant and sensitive 
typhoid fever 
Tab 4: clinical profile – signs 
Total (N 
=39)
MDR 
(N=17)
Sensitive 
(N=22)
n % n % n %
p-value
O.R. 95% C.I.
Toxic look 11 28.2 6 35.3 5 22.7 0.39 1.9 0.4 , 9.5
Coated tongue 12 30.8 6 35.3 6 27.3 0.59 1.5 0.3 , 7.1
Hepatomegaly 6 15.4 4 23.5 2 9.1 0.22 3.1 0.4 , 28.9
Splenomegaly 17 43.6 1 5.9 16 72.7 0.00 0.02 0.0 , 0.2
Hepatosplenomegaly 16 41.0 12 70.6 4 18.2 0.00 10.8 2.0 , 67.7
Lung signs 9 23.1 4 23.5 5 22.7 0.95 1.1 0.2 , 5.9
Defervescence >5 
days 14 35.9 8 47.1 6 27.3 0.20 2.4 0.5 , 11.3
Duration of hospital 
stay > 5 days 16 41.0 9 52.9 7 31.8 0.18 2.4 0.5 , 11.1
Incidence of complications among the two groups is as follows 
Tab 5: Complications
Total (N =39)
MDR 
(N=17) Sensitive (N=22)
n % n % n %
p-value
O.R. 95% C.I.
Abnormal LFT 8 20.5 7 41.2 1 4.5 0.00 14.7 1.4 , 364.6
Thrombocytopenia 9 23.1 7 41.2 2 9.1 0.02 7.0 1.0 , 60.6
Shock 2 5.1 2 11.8 - 0.0 0.09 - -
Gastrointestinal – 
hemorrhage or 
perforation 1 2.6 1 5.9 - 0.0 0.25 - -
There were no cases of clinical jaundice, encephalopathy or mortality.
The results of follow up of these patients were compared between the two groups
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Defervescence was taken as the time from admission and commencement of treatment 
to the time till fever subsided. It was observed that time taken for defervescence and duration of 
hospital stay were significantly more in the multidrug resistant group though it did not satisfy 
the statistical criteria.
The clinical profile of the eight cases of quinolone (Nalidixic acid resistant) Salmonella 
typhi were as follows 
Tab 6: clinical profile of quinolone (Nalidixic acid resistant) Salmonella typhi
 Clinical features
Quinolone resistance Total (N =8)
n %
Age <5 years 5 62.5
Fever > 7 days 6 75
Chills/Rigor 2 25
Abdominal Symptoms 3 37.5
Respiratory Symptoms 3 37.5
CNS Symptoms 2 25
Toxic look 3 37.5
Coated tongue 4 50
Hepatomegaly 3 37.5
Splenomegaly 2 25
Hepatosplenomegaly 3 37.5
Lung signs 2 25
Abnormal LFT 3 37.5
Thrombocytopenia 3 37.5
DISCUSSION:
There is a wide variation in the culture positivity rate reported from different studies in India. It 
is as low as 12% in a recent large study conducted in JIPMER 23,34 to as high as 80% in some studies. 
The culture positivity rate from the present study is 21%. This is quite an improvement compared to the 
culture positivity rates from the same institute in the preceeding years.
It  was  seen  that  the  majority  of  the  strains  grown  were  found  to  be  resistant  to 
cotrimoxazole (74.4%) and ampicillin (59%) and most strains were found to be sensitive to 
ceftriaxone (89.7%) and amikacin (87.2%). Though amikacin is not considered to be a useful 
drug against Salmonella typhi, it has shown a very high sensitivity in the invitro susceptability 
testing. Whether it is really useful in vivo either as monotherapy or as a combination especially 
in drug resistant cases needs to be determined.
Majority  of  the  strains  were  also  sensitive  to  quinolones  (79.4%)  and  cefotaxime 
(76.9%). Though there is a wide variation in chloramphenicol sensitivity reported from the 
different parts of the country, ranging from 0% sensitivity to 90% sensitivity 24,25, in the present 
study  it  is  observed  that  chloramphenicol   is  sensitive  in  56.4%.  More  importantly, 
chloramphenicol has been found to be quite sensitive in some of the quinolone resistant and 
cephalosporin  resistant  isolates.  Thus,  as  reported  in  some of  the  studies,  chloramphenicol 
sensitivity may be re-emerging and there is a constant need to monitor the sensitivity pattern of 
S.typhi isolates.
Among the 39 cultures grown, the incidence of multi-drug resistance was found to be 
43.7% (n  =  17).  Among the  17  multi-drug  resistant  strains  in  the  present  study,  15  were 
sensitive  to  ceftriaxone and 14 were  sensitive  to  quinolone.  Comparing other  studies  from 
India, the incidence of multi-drug resistant typhoid fever varied from 10% to 93% 20,21,22,23,27,28,29.
The incidence of quinolone resistance in the present study was found to be 20.5% (n = 
8).  Though  there  are  number  of  studies  from  India  reporting  the  incidence  of  multi-drug 
resistant typhoid fever,  the data on quinolone resistance is very limited  23,24,30,33.  Among the 
eight quinolone resistant cases in the present study, six were sensitive to ceftriaxone and five 
were sensitive to chloramphenicol. Among the two cases which were quinolone and ceftriaxone 
resistant, one was sensitive to chloramphenicol and the other resistant to all the other drugs, 
except amikacin and ceftazidime.
CLINICAL PROFILE
Age:  The mean age of the patients among the entire study group was 5.4 ± 2.6 years, 
while the mean age in the drug resistant group and the drug sensitive group were 4.0 ± 2.1 and 
6.4 ± 2.5 respectively. Though the total number of children < 5 years was 19 in the overall 
study group, majority (70.6%, n = 12) were in the drug resistant group and only 31.8% (n = 7) 
were in the drug sensitive group (P = 0.02).
Sex:  There were totally twenty two males and seventeen females in the study group. There was 
no difference in the sex distribution among drug resistant and sensitive groups.
There were no seasonal variation and cases occurred throughout the year indicating that typhoid 
fever is endemic in this region.
The mean duration of fever in the whole group was 6.9 ± 2.4 days, while in the drug resistant 
group it was 8.5 ± 1.9 days and it was 5.7 ± 2.0 in the drug sensitive group (P = 0.001). Though fever 
was the presenting problem in all the children, prolonged fever > 7 days was found in significantly 
major proportion in the drug resistant group (76.5%, n = 13) than in the drug sensitive group (31.8%, n 
= 7). Thus prolonged fever > 7 days was identified to be one of the important risk factor for drug 
resistance.
Though respiratory symptoms like running nose, sneezing, cough etc were found more in the 
drug resistant group (70.6% vs 36.4%), it did not meet the required statistical criteria (P > 0.05). Chills 
and rigor was found in one-third, abdominal symptoms like nausea, vomiting and loose stools were 
found in nearly half of the patients and central nervous symptoms like head-ache and letharginess were 
found in nearly 10% of the patients, without any difference between the two groups. There were no 
cases of profound loss of consciousness or seizures.
Toxic look was found in 11 out of the 39 patients and coated tongue was found in 12 patients 
without much difference between the two groups.
Isolated hepatomegaly was found in six out of the 39 children, four in the multi-drug resistant 
group and two in the drug sensitive group. Whereas isolated hepatomegaly was found only in few 
patients, isolated splenomegaly was found almost exclusive in the drug sensitive group with only one 
patient  from  drug  resistant  group  had  isolated  splenomegaly.  Hepatosplenomegaly  was  found  in 
significantly major proportion in drug resistant group (70.6%, n =12), while in the drug sensitive group 
it was only 18.2% (n = 4) (P < 0.001). It is also interesting to note that all the patients had one or other 
form of  organomegaly,  with isolated  splenomegaly predominating  in  the  drug sensitive  group and 
hepatosplenomegaly in the resistant group. Lung signs occurred in almost one-fourth of the patients, 
though equally in both the groups.
COMPLICATIONS:
Though higher complication rates have been observed in some of the studies in India  21,22,32, 
complications are few in the present study. Abnormal liver function test and thrombocytopenia were 
the two major complications observed, primarily in the multi-drug resistant group and both assuming a 
statistically significance. Though no cases of overt clinical jaundice was observed,   abnormal liver 
function in the form of mild elevation of bilirubin or more than twice the normal level of liver enzymes 
were observed in eight cases, seven in the multi-drug resistant group (41.2%) and one from sensitive 
group (4.5%) (P <0.01).
Similarly thrombocytopenia, defined by platelet count <100,000, were found in nine patients, 
significantly more in the drug resistant group (41.2%, n = 7), while two patients from drug sensitive 
group (9.1%) also had thrombocytopenia. Except for  the one patient, which presented with malena, 
none of the other had any clinical bleeding. 
Two of the patients, both from the multi-drug resistant group, had shock at presentation.  Both 
the children were corrected with two boluses of isotonic fluids. The exact reason for shock, whether it 
is fluid leak into third space, inadequate intake of oral fluids or increased loss of fluids secondary to 
high grade fever or combination of these, were not known. But both the children recovered quickly 
without any other complications .
Only one patient from the multi-drug resistant group had gastro-intestinal hemorrhage in the 
form of malena. The child also had a lowest platelet count of 85,000. The reason for the hemorrhage, 
whether due to thrombocytopenia or intestinal foci of salmonella was not known. The child had fever 
lasting for more than six days after admission, but recovered subsequently.
There were no cases of encephalopathy or other complications and there were no deaths.
FOLLOW UP :
The mean duration for defervescence was 4.1 ± 2.2 days in the overall study group, whereas it 
was 5.4 ± 1.8 in the drug resistant group and 3.1 ± 2.0 in the drug sensitive group. Thus there is a 
statistically significant prolonged duration for defervescence in the multi-drug resistant group (P = 
0.004). Similarly, the duration of hospital stay was significantly more in the multi-drug resistant group 
(6.5 ± 1.8 vs 4.9 ± 1.7) (P = 0.01).
Thus, in the present study, it is found by univariate ordinal regression that the following are the 
clinical pointers to multi-drug resistance. These include
1. Age  <  5 years
2. Prolonged fever > 7 days
3. Hepatosplenomegaly
4. Abnormal liver function test
5. Thrombocytopenia
Tab 7: clinical pointers to multi-drug resistance
Total (N 
=39)
MDR 
(N=17)
Sensitive 
(N=22)
n % n % n %
p-value
O.R.
95% 
C.I.
Age <5 
years 19 48.7 12 70.6 7 31.8 0.02 5.1
1.1 , 
26.3
Fever > 7 
days 20 51.3 13 76.5 7 31.8 0.01 7.0
1.4 , 
38.8
Hepatosplen
omegaly 16 41.0 12 70.6 4 18.2 0.00 10.8
2.0 , 
67.7
Abnormal 
LFT 8 20.5 7 41.2 1 4.5 0.00 14.7
1.4 , 
364.6
Thrombocyt
openia 9 23.1 7 41.2 2 9.1 0.02 7.0
1.0 , 
60.6
And by multiple logistic regressions it is found that fever { p = 0.007 [ O. R. = 1.8 ] and 95 % 
C.I. [ 1.2, 2.9 ] } and hepatosplenomegaly { p = 0.03 [ O. R. = 6.9 ] and 95 % C.I. [ 1.2, 38.9 ] } are 
independent risk factors for drug resistance.
Hence these risk factors might  aid  the physicians to  start  appropriate  antibiotics as per the 
prevailing antibiotic susceptibility pattern in the locality to prevent major complications.
Quinolone resistance:
Among the  eight  cases  found to  have  quinolone  resistance,  five  were  boys  and  five  were 
younger than five years (62.5 %). Similar to the multidrug resistant typhoid fever, prolonged fever of 
more than seven days were present significantly more in quinolone resistant group ( n = 6, 75% ). 
Abdominal symptoms, respiratory symptoms, toxic look and coated tongue were present in one third to 
half of these patients. While isolated splenomegaly was distinctly present in the drug sensitive typhoid 
fever and hepatosplenomegaly in the multidrug resistant group, no such difference in organomegaly 
was  present  in  quinolone  resistant  group  with  three  children  had  hepatomegaly,  three  had  both 
hepatosplenomegaly  and  two  had  isolated  splenomegaly.  While  abnormal  liver  function  test  and 
thrombocytopenia  were  observed  in  three  of  the  eight  children,  other  complications  like  shock, 
encephalopathy,  gastrointestinal  hemorrhage  or  mortality  were  not  seen  in  the  quinolone  resistant 
group.
                                                                  CONCLUSION 
1. Incidence of multidrug resistant and quinolone resistant typhoid fever was found to be 43.6% 
and 20.5% respectively which vary with time and place.  Hence there is  a constant need to 
monitor antibiotic sensitivity pattern of S.typhi and periodically review the antibiotic policy in 
the hospital and the community so as to effectively utilize these antibiotics.
2. Majority of S.typhi isolates were found to be resistant to cotrimoxazole       (74.4 %) and 
ampicillin (59 %) and most strains were observed to be sensitive to ceftriaxone (89.7%) and 
amikacin (87.2%).
3. Though amikacin was found to be sensitive in as high as 87.2%, its usefulness in vivo need to 
assessed.
4. Chloramphenicol sensitivity was observed among 56.4% of the isolates. More importantly some 
of  the  quinolone  resistant  and  ceftriaxone  resistant  strains  were  found  to  be  sensitive  to 
chloramphenicol.
5. Age  less  than  five  years,  prolonged  fever  for  more  than  seven  days,  hepatosplenomegaly, 
abnormal  liver  function  test  and  thrombocytopenia  are  specific  risk  factors  for  multidrug 
resistant  typhoid  fever  and  need  early  and  aggressive  management  for  prevention  of 
complications.
6. Quinolone resistance may be a problem in future in typhoid fever and specific risk factors and 
alternative therapeutic strategies need to be evaluated.
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ANNEXURE
PROFORMA
S.No:
 Name: Age: Sex:
 I.P.No: DOA:
 Address:  
Clinical Features:
H/O 
   Fever:
          Duration:
Pattern:
Associated chills/rigor:
   Bowel habits( Constipation / Diarrhea): 
   Vomiting:
   Abdominal   pain:
   Abdominal distension:
   Cough:
   Anorexia:
   Joint pain:
   Myalgia:
   Epistaxis:
   Headache:
   Alteration in mental status:
  Seizures:
          Loss of consciousness:
   H/o contact with known typhoid fever:
   Prior treatment H/O:
   Immunization H/O:
 
Vital Signs:
PR:
BP:
RR:
Temperature:
General Examination:
Anemia:
Jaundice:
Edema:
Lymphadenopathy:
Toxic Look:
Rose Spot:
Coated Tongue:
Others:
Systemic Examination:
 Abdomen:
 
Respiratory System:
  
Cardio Vascular System:
 
Central Nervous System:
  
Musculoskeletal:
Investigations:
CBC: Urine R/E:
  C & S :
 PS-MP: CXR :
  LFT: Mantoux:
CSF analysis:
 Blood culture:
Organism:
Sensitivity pattern:
Stool culture:
 Others:
 Treatment:
Follow up :
Features D1 D2 D3 D4 D5 D6 D7
Fever
Organome
galy
Complicati
ons
Hospital 
stay

